Insulin microcrystals were encapsulated (microcrystal/PLGA) within poly(lactide-co-glycolide) (PLGA 50:50) by the multiple emulsification solvent evaporation technique and compared with insulin solution microspheres (solution/PLGA) in terms of their morphology, size distribution, drug content, encapsulation efficiency, and stability of insulin during release.
The study of protein-loaded microspheres for drug delivery has been a field of intensive research. The main advantages of using biodegradable microspheres as a drug delivery vehicle are the protection from proteolysis and sustained drug-release profile. To optimize these advantages for specific drugs, biodegradable polymers such as polylactide (PLA), poly-DL-lactide-co-poly-(ethylene glycol) (PELA) and poly(lactide-co-glycolide) (PLGA) have been extensively investigated. [1] [2] [3] However, during the preparation of protein-loaded microspheres, the protein is often exposed to such unfavorable conditions as mechanical stirring and organic solvents. As a result, varying molecular deterioration of the protein, for instance denaturation, aggregation, chemical degradation and adsorption to the polymer surface, have been observed. 4, 5) In order to overcome the activity loss of proteins during the process, a number of studies have focused on the chemical modification of proteins, protein stabilizers, and surfactants; however, drawbacks, like an uncontrolled initial burst, were also observed. 6, 7) The microcrystallization of bovine insulin has recently been developed in our laboratory. 8) It is well known that protein crystallization results in the formation of a lattice structure with the protein molecule. Direct interaction between protein molecules is relatively weak in most crystals, thus minimizing the loss of biological activity. 9) In this work, bovine insulin microcrystals were selected in order to test the feasibility of protein crystals as a model for encapsulation into PLGA (microcrystal/PLGA), and its advantages were investigated.
To prepare the insulin microcrystals, bovine insulin (1 mg/ml) was dissolved in 0.1 N acetic acid (pH 2), and the pH value was increased by adding 1 N NaOH. Once it had reached pH 10.5, the value was adjusted down to pH 6. 8) Microcrystal/PLGA was prepared by using a PLGA 50:50 copolymer (MW 40,000-75,000) with the double-emulsification solvent evaporation procedure. 10) A primary emulsion of microcrystal suspension (3.5% w/v, 300 l) in acetic acid (0.1 N, pH 6.0) and a polymer solution (5% w/v, 4 ml) in dichloromethane was prepared by homogenization (Tissue-TearoÔ, BioSpec Products, OK, USA). The primary emulsion was stabilized by further emulsification in a polyvinylalcohol solution (1%, w/v) to get a secondary emulsion (w/o/w type). After the organic solvent had been evaporated, the resulting microspheres were washed and freeze-dried. An insulin solution was also encapsulated by the same method. The PLGA microspheres were dispersed in distilled water and sized by laser diffraction with a 1064 instrument (CILAS, France). The morphology of the microspheres was analyzed by scanning electron microscopy (SEM; Jeol JSM-5300, Japan). To measure the protein content, a known weight of microcapsules was dissolved in 500 l of DCM and extracted twice with 1 ml of acetic acid (0.1 N). The insulin concentration was determined spectrophotometrically at 595 nm by the Bradford method. To measure the stability of the insulin during release, ten milligrams of microcapsules were suspended in 0.4 ml of phosphate-buffered saline (PBS) and allowed to stand at 37 C without agitation. After 7 days, the supernatant was collected by centrifugation and analyzed by reversed-phase high-performance liquid chromatography (HPLC). A Cl8 column (Waters, BondapakÔ C18, 3.8 mm IDÂ30 cm) was used to detect deamidated insulin. Gradient elution was employed by using a linear gradient of 1% trifluoroacetic acid to 60% acetonitrile over 20 minutes. The flow rate was 1.0 ml/min and the eluate was monitored by UV detection at 280 nm. Size-exclusion chromatography (Supelco, TSK-GEL 1 G2000SW, 7.5 mm IDÂ60 cm) was performed to detect the aggregated insulin impurities. Gradient elution was employed with a 1.16 M * These authors contributed equally to this work.
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The mean diameter of microcrystals was 3:0 AE 0:9 m, and the crystallization yield was maintained at 90% or higher. The shape of a microcrystal was homogeneous rhombohedral. No amorphous particles or aggregates were apparent. Both types of microsphere displayed a smooth, spherical surface (Fig. 1A, B) , but the solution/PLGA showed a more porous surface. The mean size of solution/PLGA was 6:6 AE 0:4 m and that of the microcrystal/PLGA was 5:1 AE 0:9 m. It is well known that the size of a microsphere depends upon the mixing speed, 11) volume of the external aqueous phase, 12) polymer concentration in the organic phase, 13) and mixing method used to prepare the W 1 /O or W 1 /O/ W 2 emulsion. 14) In our study, all of these conditions remained constant, the except for the physical state of the insulin in the first aqueous phase, dissolved form (for the solution/PLGA) and crystal form (for the microcrystal/PLGA). The size difference between both types of microsphere may have been caused by the mass effect of the microcrystals in the first aqueous phase (W1). During preparation of the solution/PLGA microspheres, the size of the primary emulsion was variable because there were no solid particles in the first aqueous phase. In the primary emulsion, minor emulsions could have been trapped together in the secondary emulsion resulting in a multi-cavity structure (Fig. 1C) . On the other hand, the size of the primary emulsion when using the microcrystal suspension was less variable, due to the fact that the microcrystals did not become trapped together in the primary emulsion (Fig. 1D) . It is thus suggested that the physical state of a drug such as insulin could affect the size, variability, and internal structure of the microsphere preparation.
To investigate the effect of microcrystals on the drug content, the insulin content was measured. Increasing the concentration of insulin produced a higher drug content in both preparations. With a low insulin loading (10 mg/ml), there was no significant difference between the solution/PLGA (1:1 AE 0:2%) and microcrystal/ PLGA (1:1 AE 0:3%). However, with a 50 mg/ml loading, the insulin content of the solution/PLGA was 3:3 AE 0:7%, while that of the microcrystal/PLGA was 5:8 AE 0:7% (Fig. 2 , P < 0:01 by an unpaired t-test). In practice, it is difficult to increase the drug content of solution/PLGA microspheres because the solubility of insulin is limited by the given buffer conditions. However, since there is no solubility limitation in the case of a microcrystal suspension, the formation of microsphere with high drug content is possible. In addition to the insulin content, the insulin loss during the hardening process was measured. To investigate the insulin loss, each formulation was collected during the hardening process at scheduled times. Each sample was then separated into its microspheres and external aqueous phase (OWP) components, and the insulin content was measured for each. The insulin content of the solution/PLGA microspheres was decreased by 18.8%, while the insulin content of the microcrystal/ PLGA microspheres was decreased by only 1.3%. These results are supported by the change in the OWP insulin content (data not shown). Encapsulation efficiency of both formulations is reported in Table 1 . With a low insulin loading (10 mg/ml), the encapsulation efficiency of solution/PLGA and microcrystal/PLGA was similar, 72:9 AE 8:0% and 74:0 AE 8:9%, respectively. However, as the insulin concentration was increased, the encapsulation efficiency of solution/PLGA decreased to 42:8 AE 6:9%, while that of microcrystal/PLGA remained constant (79:9 AE 8:0%).
The predominant types of denaturation in the microencapsulation of insulin include deamidation and covalent dimerization. 15) To test the influence of crystals on the insulin stability during its in vitro release, the amount of insulin released from the microspheres was analyzed by reverse-phase and size-exclusion HPLC after 7 days. The size-exclusion analysis showed no insulin aggregation products such as covalently dimerized insulin in either type of microsphere. However, the reverse-phase analysis showed desamido insulin in both types of microsphere. The desamido insulin level was 6:8 AE 0:6% (see the method for calculation) in solution/ PLGA, while that of microcrystal/PLGA was significantly lower at 1:3 AE 0:2%. This latter value is below the British Pharmacopoeia allowable level of less than 3%.
16) The freeze-dried microspheres also showed similar percentages of desamido insulin: 6:5 AE 3:1% in solution/PLGA and 2:0 AE 0:5% in crystal/PLGA. There are several reasons why improved insulin stability was noted in the microcrystal preparation. First, crystallized insulin has a smaller contact area with the organic solvent layer during the emulsifying process. Second, the lattice structure of the crystals efficiently inhibits protein migration to the aqueous/organic interface during processing. Third, the shell thickness of microcrystal/PLGA is relatively homogeneous in structure, preventing early microsphere wall breakdown (Fig. 1) . Any or all of these three phenomena may have protected the insulin from absorption to the polymer barrier as well as from the acidic environment created by polymer breakdown.
The use of a microcrystal suspension as the first aqueous phase can enhance both the microsphere properties and the stability of a loaded protein. Improvements during microspheres preparation may include decreasing the microsphere size, increasing the drug content per microsphere, and concentration-dependent enhancement of the encapsulation efficiency. The stability of protein has already been significantly improved. 
